World Health Organization. Regulations and laws promoting health and well-being goals (SDG3) in WHO South-East Asian countries. New Delhi, 2022. https://apps.who.int/iris/rest/bitstreams/1461864/retrieve. Accessed 2 Dec 2023.

Trifirò G, Crisafulli S. A new era of pharmacovigilance: future challenges and opportunities. Front Drug Saf Regul. 2022;2: 866898. https://doi.org/10.3389/fdsfr.2022.866898.

Article  Google Scholar 

Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions”. J Pharmacol Pharmacother. 2013;4(1_Suppl):S73–7. https://doi.org/10.4103/0976-500X.120957.

Article  PubMed  PubMed Central  Google Scholar 

US Centers for Disease Control and Prevention. About the Vaccine Adverse Event Reporting System (VAERS). https://wonder.cdc.gov/controller/datarequest/D8. Accessed 9 Jun 2023.

Medicine & Healthcare products Regulatory Agency (MHRA). The Yellow Card Scheme: MHRA. https://yellowcard.mhra.gov.uk/information. Accessed 8 Jun 2023.

Ball R, Dal Pan G. Artificial intelligence’ for pharmacovigilance: ready for prime time? Drug Saf. 2022;45(5):429–38. https://doi.org/10.1007/s40264-022-01157-4.

Article  PubMed  PubMed Central  Google Scholar 

Rudolph A, Savage R. Vulval aphthous ulcers in adolescents following COVID-19 vaccination: analysis of an international case series. J Pediatr Adolesc Gynecol. 2023. https://doi.org/10.1016/j.jpag.2023.03.006.

Article  PubMed  PubMed Central  Google Scholar 

Krapf JM, Casey RK, Goldstein AT. Reactive non-sexually related acute genital ulcers associated with COVID-19”. BMJ Case Rep. 2021;14(5): e242653.

Article  PubMed  PubMed Central  Google Scholar 

Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifirò G. Challenges for drug repurposing in the COVID-19 pandemic era. Front Pharmacol. 2020;11: 588654. https://doi.org/10.3389/fphar.2020.588654.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lumpkin MM, Lim JCW. Pandemic best regulatory practices: an urgent need in the COVID-19 pandemic. Clin Pharmacol Ther. 2020;108(4):703–5. https://doi.org/10.1002/cpt.1932.

Article  CAS  PubMed  Google Scholar 

Bolislis WR, de Lucia ML, Dolz, et al. Regulatory agilities in the time of COVID-19: overview, trends, and opportunities. Clin Ther. 2021;43(1):124–39. https://doi.org/10.1016/j.clinthera.2020.11.015.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Fitzpatrick T, Wan B, Day S, Mathews A, Tucker JD. Forming and implementing community advisory boards in low- and middle-income countries: a scoping review. BMC Med Ethics. 2019;20(1):73. https://doi.org/10.1186/s12910-019-0409-3.

Article  PubMed  PubMed Central  Google Scholar 

Yue Q-Y. The International Society of Pharmacovigilance (ISoP) Pharmacogenomic Special Interest Group: pharmacogenomics in pharmacovigilance. Drug Saf. 2021;44(6):615–7. https://doi.org/10.1007/s40264-021-01068-w.

Article  PubMed  PubMed Central  Google Scholar 

Cavaller-Bellaubi M, Faulkner SD, Teixeira B, et al. Sustaining meaningful patient engagement across the lifecycle of medicines: a roadmap for action. Ther Innov Regul Sci. 2021;55(5):936–53. https://doi.org/10.1007/s43441-021-00282-z.

Article  PubMed  PubMed Central  Google Scholar 

Patient involvement in the development, regulation and safe use of medicines. CIOMS Working Group report. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS), 2022. https://doi.org/10.56759/iiew8982.

World Health Organization. Global patient safety action plan 2021–2030: towards eliminating avoidable harm in health care. Geneva, 2021. https://www.who.int/teams/integrated-health-services/patient-safety/policy/global-patient-safety-action-plan. Accessed 2 Dec 2023.

Adopo D, Daynes P, Benkebil M, et al. Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France. Eur J Clin Pharmacol. 2023;79(2):229–36. https://doi.org/10.1007/s00228-022-03422-y.

Article  CAS  PubMed  Google Scholar 

Berrewaerts J, Delbecque L, Orban P, Desseilles M. Patient participation and the use of Ehealth tools for pharmacoviligance. Front Pharmacol. 2016;7:90. https://doi.org/10.3389/fphar.2016.00090.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paola K, Claudio G. The value of direct patient reporting in pharmacovigilance. Ther Adv Drug Saf. 2020;11:2042098620940164. https://doi.org/10.1177/2042098620940164.

Article  PubMed  PubMed Central  Google Scholar 

Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review: the value of patient reporting to the pharmacovigilance system. Br J Clin Pharmacol. 2017;83(2):227–46. https://doi.org/10.1111/bcp.13098.

Article  PubMed  Google Scholar 

Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–56. https://doi.org/10.1111/j.1365-2125.2006.02746.x.

Article  CAS  PubMed  Google Scholar 

Suwankesawong W, Dhippayom T, Tan-Koi W-C, Kongkaew C. Pharmacovigilance activities in ASEAN countries. Pharmacoepidemiol Drug Saf. 2016;25(9):1061–9. https://doi.org/10.1002/pds.4023.

Article  PubMed  Google Scholar 

Hugman B. The Erice Declaration: the critical role of communication in drug safety. Drug Saf. 2006;29(1):91–3. https://doi.org/10.2165/00002018-200629010-00007.

Article  PubMed  Google Scholar 

Kim Y-S, Kim HA, Kim M-S, et al. How to improve patient safety literacy? Int J Environ Res Public Health. 2020;17(19):7308. https://doi.org/10.3390/ijerph17197308.

Article  PubMed  PubMed Central  Google Scholar 

Edwards IR. A new Erice Report considering the safety of medicines in the 21st century. Drug Saf. 2017;40(10):845–9. https://doi.org/10.1007/s40264-017-0571-9.

Article  PubMed  PubMed Central  Google Scholar 

Härmark L, Weits G, Meijer R, Santoro F, Norén GN, van Hunsel F. Communicating adverse drug reaction insights through patient organizations: experiences from a pilot Study in the Netherlands. Drug Saf. 2020;43(8):745–9. https://doi.org/10.1007/s40264-020-00932-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Hoof M, Chinchilla K, Härmark L, Matos C, Inácio P, van Hunsel F. Factors contributing to best practices for patient involvement in pharmacovigilance in Europe: a stakeholder analysis. Drug Saf. 2022;45(10):1083–98. https://doi.org/10.1007/s40264-022-01222-y.

Article  PubMed  PubMed Central  Google Scholar 

European Patients’ Academy on Therapeutic Innovation. Patient involvement in EMA regulatory committees. https://toolbox.eupati.eu/resources/patient-involvement-in-ema-regulatory-committees/. Accessed 4 Jun 2023.

The Centre of Regulatory Excellence. Integrating patient engagement into healthcare and access to medicines in the Asia Pacific Region. Duke-NUS Medical School, Oct. 2019. https://www.duke-nus.edu.sg/core/think-tank/news/integrating-patient-engagement-into-healthcare-and-access-to-medicines-in-the-asia-pacific-region. Accessed 8 Jun 2023.

Pitts PJ, Le Louet H. Advancing drug safety through prospective pharmacovigilance. Ther Innov Regul Sci. 2018;52(4):400–2. https://doi.org/10.1177/2168479018766887.

Article  PubMed  Google Scholar 

The Centre of Regulatory Excellence. Accelerating patient engagement for more resilient health systems. Duke-NUS Medical School, Nov. 2020. https://www.duke-nus.edu.sg/core/think-tank/news/regional-multi-stakeholder-roundtable-report-accelerating-patient-engagement-for-more-resilient-health-systems. Accessed 8 Jun 2023.

Bahri P, Morales DR, Inoubli A, Dogné J-M, Straus SMJM. Proposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Saf. 2021;44(2):193–209. https://doi.org/10.1007/s40264-020-01005-3.

Article  PubMed  Google Scholar 

Bahri P, Pariente A. Systematising pharmacovigilance engagement of patients, healthcare professionals and regulators: a practical decision guide derived from the International Risk Governance Framework for Engagement Events and Discourse. Drug Saf. 2021;44(11):1193–208. https://doi.org/10.1007/s40264-021-01111-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Worakunphanich W, Youngkong S, Suwankesawong W, Anderson C, Thavorncharoensap M. Comparison of patient adverse drug reaction reporting systems in nine selected countries. Int J Environ Res Public Health. 2022;19(8):4447. https://doi.org/10.3390/ijerph19084447.

Article  PubMed  PubMed Central  Google Scholar 

Kitabayashi A, Inoue Y. Factors that lead to stagnation in direct patient reporting of adverse drug reactions: an opinion survey of the general public and physicians in Japan. Ther Innov Regul Sci. 2022;56(4):616–24. https://doi.org/10.1007/s43441-022-00397-x.

Article  PubMed  PubMed Central  Google Scholar 

Kiguba R, Mwebaza N, Ssenyonga Ronald, et al. Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. BMJ Open. 2022;12(7):e061725. https://doi.org/10.1136/bmjopen-2022-061725.

Article  PubMed  PubMed Central  Google Scholar 

Munshi R, Maurya M, Pawaskar P. Public awareness and perception about drug safety in the population residing in Western India: a questionnaire based cross sectional survey. Biomed Pharmacol J. 2022;15(4):1937–45. https://doi.org/10.13005/bpj/2532.

Article  Google Scholar 

Arnstein SR. A ladder of citizen participation. J Am Inst Plann. 1969;35(4):216–24. https://doi.org/10.1080/01944366908977225.

Article  Google Scholar 

Bammer G. Stakeholder engagement: learning from Arnstein’s ladder and the IAP2 spectrum. https://i2insights.org/2022/08/30/learning-from-arnsteins-ladder-and-iap2-spectrum/. Accessed 10 Jun 2023.